Glypressin® 1mg, powder and solvent for solution for injection
Terlipressin Acetate 1mg, powder and solvent for solution for injection
Each vial contains 1mg Terlipressin Acetate
For excipients, see 6.1
Powder and solvent for solution for injection
Vial contains white, freeze-dried powder.
Ampoule contains solvent.
Glypressin® is indicated in the treatment of bleeding oesophageal varices.
In acute variceal bleeding:
Adults:Initially an i.v. injection of 2 mg Glypressin is given every 4 hours. The treatment should be maintained until bleeding has been controlled for 24 hours, but up to a maximum of 48 hours. After the initial dose, the dose can be adjusted to 1 mg i.v. every 4 hours in patients with body weight < 50 kg or if adverse effects occur.
There is no relevant use of Glypressin in paediatric population.
Method of administration
Intravenous injection use
Contraindicated in pregnancy.
Hypersensitivity to terlipressin acetate or any of the excipients listed in section 6.1.
Blood pressure, heart rate and fluid balance should be monitored during treatment.
To avoid local necrosis at the injection site, the injection must be given i.v.
Caution should be exercised in treating patients with hypertension or recognised heart disease.
In patients with septic shock with a low cardiac output Glypressin should not be used.
Torsade de pointes
During clinical trials and post-marketing experience, several cases of QT interval prolongation and ventricular arrhythmias including "Torsade de pointes" have been reported (see section 4.8). In most cases, patients had predisposing factors such as basal prolongation of the QT interval, electrolyte abnormalities (hypokalemia, hypomagnesemia) or medications with concomitant effect on QT prolongation. Therefore, extreme caution should be exercised in the use of terlipressin in patients with a history of QT interval prolongation, electrolyte abnormalities, or concomitant medications that can prolong the QT interval (see section 4.5).
Children and the elderly: Particular caution should be exercised in the treatment of children and elderly patients, as experience is limited in these groups.
There is no data available regarding dosage recommendation in these special patient categories.
The hypotensive effect of non-selective beta-blockers on the portal vein is increased with terlipressin. Concomitant treatment with medicinal products with a known bradycardic effect (e.g. propofol, sufentanil) may lower the heart rate and cardiac output. These effects are due to reflexogenic inhibition of cardiac activity via the vagus nerve due to the elevated blood pressure.
Terlipressin can trigger "torsade de pointes" (see sections 4.4 and 4.8). Therefore, extreme caution should be exercised in the use of terlipressin in patients with concomitant medications that can prolong the QT interval, such as class IA and III antiarrhythmics, erythromycin, certain antihistamines and tricyclic antidepressants or medications that may cause hypokalaemia or hypomagnesemia (e.g. some diuretics).
Treatment with Glypressin during pregnancy is contraindicated (ref. 4.3 and 5.3).
Glypressin has been shown to cause uterine contractions and increased intrauterine pressure in early pregnancy and may decrease uterine blood flow. Glypressin may have harmful effects on pregnancy and foetus.
Spontaneous abortion and malformation have been shown in rabbits after treatment with Glypressin.
It is not known whether terlipressin is excreted in human breast milk. The excretion of terlipressin in milk has not been studied in animals. A risk to the suckling child cannot be excluded. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with terlipressin should be made taking into account the benefit of breast-feeding to the child and the benefit of terlipressin therapy to the woman.
No studies on the effects on the ability to drive and use machines have been performed.
Table: Frequency of undesirable effects
SYSTEM ORGAN CLASS
≥1/100 to <1/10
≥ 1/1,000 to < 1/100
≥1/10,000 to ≤1/1,000
Metabolism and nutrition disorders
Hyponatraemia if fluid not monitored
Nervous system Disorders
Fluid overload with pulmonary oedema
Torsade de pointes
Respiratory thoracic and mediastinal disorders
Transient abdominal cramps
Skin and subcutaneous tissue disorders
Pregnancy, puerperium and perinatal conditions
General disorders and administration site disorders
Injection site necrosis
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard.
The recommended dose (2mg/4 hours) should not be exceeded as the risk of severe circulatory adverse effects is dose-dependent.
Pharmacotherapeutic group: Posterior pituitary lobe hormones (vasopressin and analogues) (H 01 BA 04)
Glypressin® may be regarded as a circulating depot of lysine vasopressin. Following intravenous injection, three glycyl moieties are enzymatically cleaved from the N-terminus to release lysine vasopressin.
The slowly released vasopressin reduces blood flow in the splanchnic circulation in a prolonged manner, thereby helping to control bleeding from ruptured oesophageal varices.
Glypressin® is administered by bolus iv injection. It shows a biphasic plasma level curve which indicates that a two compartment model can be applied.
The half-life of distribution (T1/2α) is about 8 -10 minutes.
The half-life of elimination (T1/2β) is about 50 -70 minutes.
Lysine vasopressin reaches maximum plasma levels about 1 - 2 hours following iv administration and has a duration of activity of 4 - 6 hours.
There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
Hydrochloric Acid 1M
Hydrochloric Acid 1M
Water for Injection
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Do not store above 25°C. Keep container in the outer carton.
Powder: Type I glass vial
Solvent: Type I glass ampoule
Cartons containing 5 packs, each with one vial of powder and one ampoule of 5ml solvent.
Unused drug and waste should be destroyed in accordance with local requirements.
Any unused product or waste material should be disposed of in accordance with local requirements.
Ferring Pharmaceuticals Ltd.
18th July 2001